Baker Bros. Advisors Adds $116M in GRAIL, Inc. ($GRAL)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors increased its position in GRAIL, Inc. ($GRAL) by 93.19% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,028,614 shares of GRAIL, Inc. after buying 1,943,281 shares during the quarter. Baker Bros. Advisors's holdings in GRAIL, Inc. were worth $241.11 million as of its most recent filing.
GRAIL, Inc. Stock Down 25.2%
Shares of GRAIL, Inc. ($GRAL) traded around $59.85 on Saturday, down 25.2% for the day.
GRAIL, Inc. Earnings
Analysts Set New Price Targets
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Get GRAIL, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GRAL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.